Dr Jorja Braden is a Medical Oncologist and current PhD student. Her research focuses on how targeted therapy alters the tumour microenvironment and how these changes influence responses to immunotherapy. Utilising samples from the NeoTrio clinical trial, Dr Braden is conducting an in-depth multi-omic investigation of both the tumour microenvironment and the peripheral immune system to characterise changes associated with sequencing or concurrent targeted therapy with anti–PD-1.